The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia

Document Details

Document Type
Pub Defense Publication
Publication Date
Oct 01, 2018
Source ID
10.1016/j.neuropharm.2018.09.005

Entities

People

  • Andrew J. Flores
  • Brandon K. Root
  • Frank Porreca
  • Kate L. Parent
  • Michael L. Heien
  • Mitchell J. Bartlett
  • Robin Polt
  • Scott J. Sherman
  • Torsten Falk

Organizations

  • Achievement Rewards for College Scientists Foundation
  • National Institutes of Health
  • National Science Foundation
  • Office of Naval Research